Alnylam Pharmaceuticals, Inc. (ALNY) Earnings History
Annual and quarterly earnings data from 2002 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 81.8% | 13.5% | 8.4% |
| 2024 | 85.6% | -7.9% | -12.4% |
| 2023 | 83.0% | -15.4% | -24.1% |
| 2022 | 83.7% | -75.7% | -109.0% |
| 2021 | 83.4% | -83.9% | -101.0% |
Download Data
Export ALNY earnings history in CSV or JSON format
Free sign-in required to download data
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings Overview
As of February 28, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) reported trailing twelve-month net income of $314M, reflecting +2.1% year-over-year growth. The company earned $2.30 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, ALNY's historical earnings data spans multiple years. The company achieved its highest annual net income of $314M in fiscal 2025, representing a new all-time high.
Alnylam Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 0.8%, operating margin of 0.1%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), CRSP (-$488M net income, -165.7% margin), ALNY has outperformed on profitability metrics. Compare ALNY vs IONS →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $314M | +212.8% | $502M | $2.33 | 8.4% | 13.5% |
| 2024 | -$278M | +36.8% | -$177M | $-2.18 | -12.4% | -7.9% |
| 2023 | -$440M | +61.1% | -$282M | $-3.52 | -24.1% | -15.4% |
| 2022 | -$1.13B | -32.6% | -$785M | $-9.30 | -109.0% | -75.7% |
| 2021 | -$853M | +0.6% | -$709M | $-7.20 | -101.0% | -83.9% |
| 2020 | -$858M | +3.1% | -$828M | $-7.46 | -174.1% | -168.1% |
| 2019 | -$886M | -16.4% | -$939M | $-8.11 | -403.2% | -427.5% |
| 2018 | -$761M | -55.1% | -$815M | $-7.57 | -1016.6% | -1087.6% |
| 2017 | -$491M | -19.7% | -$500M | $-5.42 | -545.9% | -556.2% |
| 2016 | -$410M | -41.4% | -$425M | $-4.79 | -869.6% | -900.3% |
See ALNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALNY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ALNY vs AGIO
See how ALNY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ALNY growing earnings?
ALNY EPS of $2.30 reflects slowing growth at +2.1%, below the 5-year CAGR of N/A. TTM net income is $314M. Expansion rate has moderated.
What are ALNY's profit margins?
Alnylam Pharmaceuticals, Inc. net margin is +0.1%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are ALNY's earnings?
ALNY earnings data spans 2002-2025. The current earnings trend is +2.1% YoY. Historical data enables comparison across business cycles.